Moreover, chromatin accessibility at the FOXJ2 promoter was specifically augmented in the in vitro APS model but was attenuated by OICR‐9429 treatment (Figure 1F). This evidence concerns the gene FOXJ2 and autoimmune polyendocrinopathy.